Transport characteristics of guanidino compounds at the blood-brain barrier and blood-cerebrospinal fluid barrier: relevance to neural disorders
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Guanidino compounds (GCs), such as creatine, phosphocreatine, guanidinoacetic acid, creatinine, methylguanidine, guanidinosuccinic acid, γ-guanidinobutyric acid, β-guanidinopropionic acid, guanidinoethane sulfonic acid and α-guanidinoglutaric acid, are present in the mammalian brain. Although creatine and phosphocreatine play important roles in energy homeostasis in the brain, accumulation of GCs may induce epileptic discharges and convulsions. This review focuses on how physiologically important and/or neurotoxic GCs are distributed in the brain under physiological and pathological conditions. Transporters for GCs at the blood-brain barrier (BBB) and the blood-cerebrospinal fluid (CSF) barrier (BCSFB) have emerged as substantial contributors to GCs distribution in the brain. Creatine transporter (CRT/solute carrier (SLC) 6A8) expressed at the BBB regulates creatine concentration in the brain, and represents a major pathway for supply of creatine from the circulating blood to the brain. CRT may be a key factor facilitating blood-to-brain guanidinoacetate transport in patients deficient in S-adenosylmethionine:guanidinoacetate N-methyltransferase, the creatine biosynthetic enzyme, resulting in cerebral accumulation of guanidinoacetate. CRT, taurine transporter (TauT/SLC6A6) and organic cation transporter (OCT3/SLC22A3) expressed at the BCSFB are involved in guanidinoacetic acid or creatinine efflux transport from CSF. Interestingly, BBB efflux transport of GCs, including guanidinoacetate and creatinine, is negligible, though the BBB has a variety of efflux transport systems for synthetic precursors of GCs, such as amino acids and neurotransmitters. Instead, the BCSFB functions as a major cerebral clearance system for GCs. In conclusion, transport of GCs at the BBB and BCSFB appears to be the key determinant of the cerebral levels of GCs, and changes in the transport characteristics may cause the abnormal distribution of GCs in the brain seen in patients with certain neurological disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Creatine and Creatinine Metabolism
Wyss, M., & Kaddurah-Daouk, R. (2000) · Physiological Reviews · doi:10.1152/physrev.2000.80.3.1107 · Cited by 2,950 · cited 2×
“In this CT/PCT/CT kinase shuttle system, the phosphate-bound energy of ATP is transferred to CT and stored as PCT to be used for regenerating ATP from ADP [4].”
Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis
Klivenyi, P., Ferrante, R. J., Matthews, R. T., Bogdanov, M. B., Klein, A. M., Andreassen, O. A., Mueller, G., Wermer, M., Kaddurah-Daouk, R., & Beal, M. F. (1999) · Nature Medicine · doi:10.1038/6568 · Cited by 682
Creatine deficiency in the brain: A new, treatable inborn error of metabolism
Stöckler, S., Holzbach, U., Hanefeld, F., Marquardt, I., Helms, G., Requart, M., Hänicke, W., & Frahm, J. (1994) · Pediatric Research · doi:10.1203/00006450-199409000-00023 · Cited by 417 · cited 17×
“Such information should also aid the discovery and development of drugs which facilitate efflux transport of GCs at the BBB and the BCSFB in order to prevent accumulation of GCs, as well as drugs which facilitate the influx transport of CT at the BBB to promote efficient supplementation of CT. Abbreviations AGAT: L-ar…”
InfluentialNa+-dependent Glutamate Transporters (EAAT1, EAAT2, and EAAT3) of the Blood-Brain Barrier
O'Kane, R. L., Martı́nez-López, I., DeJoseph, M. R., Viña, J. R., & Hawkins, R. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.31891 · Cited by 268
Stöckler, S., Hanefeld, F., & Frahm, J. (1996) · The Lancet · doi:10.1016/s0140-6736(96)04116-5 · Cited by 240
Brewer, G. J., & Wallimann, T. W. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0741968.x · Cited by 230
Increase of total creatine in human brain after oral supplementation of creatine-monohydrate
Dechent, P., Pouwels, P. J. W., Wilken, B., Hanefeld, F., & Frahm, J. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.277.3.r698 · Cited by 221
Glutamine transport by the blood-brain barrier: a possible mechanism for nitrogen removal
Lee, W.-J., Hawkins, R. A., Viña, J. R., & Peterson, D. R. (1998) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1998.274.4.c1101 · Cited by 191 · cited 1×
“When the glutamate concentration in endothelial cells becomes greater than that in the plasma, glutamate would be effluxed from the endothelial cells into the circulating blood in a facilitative manner [42,43].”
Cerebral creatine deficiency syndromes: Clinical aspects, treatment and pathophysiology
Stockler, S., Schutz, P. W., & Salomons, G. S. (2007) · Subcellular Biochemistry · doi:10.1007/978-1-4020-6486-9_8 · Cited by 180 · cited 1×
“Relevance of GCs transport at the brain barriers to neural disorders A physiological importance of CT in the brain has been evidenced in inherited CT deficiency syndrome (CDS), which is characterized by the absence or severe reduction of CT in the brain [7].”
PROGRESS IN UREMIC TOXIN RESEARCH: Guanidino Compounds as Uremic (Neuro)Toxins
De Deyn, P. P., Vanholder, R., Eloot, S., & Glorieux, G. (2009) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2009.00577.x · Cited by 131 · cited 2×
“Several GCs, such as CTN, MG, guanidine, and GSA, are involved in the typical manifestations, such as epileptic and cognitive symptoms, of uremic encephalopathy [82].”
Cited by
Creatine biosynthesis and transport in health and disease
Joncquel-Chevalier Curt, M., Voicu, P.-M., Fontaine, M., Dessein, A.-F., Porchet, N., Mention-Mulliez, K., Dobbelaere, D., Soto-Ares, G., Cheillan, D., & Vamecq, J. (2015) · Biochimie · doi:10.1016/j.biochi.2015.10.022 · Cited by 238
Microbiota from Alzheimer’s patients induce deficits in cognition and hippocampal neurogenesis
Grabrucker, S., Marizzoni, M., Silajdžić, E., Lopizzo, N., Mombelli, E., Nicolas, S., Dohm-Hansen, S., Scassellati, C., Moretti, D. V., Rosa, M., et al. (2023) · Brain · doi:10.1093/brain/awad303 · Cited by 236
Creatine Supplementation and Brain Health
Roschel, H., Gualano, B., Ostojic, S. M., & Rawson, E. S. (2021) · Nutrients · doi:10.3390/nu13020586 · Cited by 174
Diémé, B., Mavel, S., Blasco, H., Tripi, G., Bonnet-Brilhault, F., Malvy, J., Bocca, C., Andres, C. R., Nadal-Desbarats, L., & Emond, P. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00699 · Cited by 122
Creatine and guanidinoacetate transport at blood-brain and blood-cerebrospinal fluid barriers
Braissant, O. (2012) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-011-9433-2 · Cited by 112
“…Cr synthesis pathway is invalidated in AGAT and GAMT deficiencies, the low levels of Cr found in the brain of their respective patients must enter the brain at BBB, through SLC6A8 expressed in MCEC, with the limited efficacy described above (Braissant and Henry 2008; Tachikawa and Hosoya 2011).”
BackgroundInfluential
Metadata
- Authors
- Tachikawa, M., & Hosoya, K.-I.
- Venue
- Fluids and Barriers of the CNS
- Published
- 2011-02-28
- Volume
- 8
- Issue
- 1
- Pages
- 13-13
- ISSN
- 2045-8118 (ISSN-L)
- OpenAlex
- W2169452196
- Cited by
- 95
- References
- 10
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Transport characteristics of guanidino compounds at the blood-brain barrier and blood-cerebrospinal fluid barrier: relevance to neural disorders. https://app.cochat.ai/papers/10.1186/2045-8118-8-13
- The paper
- Tachikawa, M., & Hosoya, K.-I. (2011). Transport characteristics of guanidino compounds at the blood-brain barrier and blood-cerebrospinal fluid barrier: relevance to neural disorders. Fluids and Barriers of the CNS. https://doi.org/10.1186/2045-8118-8-13
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.